These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27510248)

  • 1. Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.
    Hsiang E; Little KM; Haguma P; Hanrahan CF; Katamba A; Cattamanchi A; Davis JL; Vassall A; Dowdy D
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1212-8. PubMed ID: 27510248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing laboratory costs of smear/culture and Xpert
    Naidoo P; Dunbar R; du Toit E; van Niekerk M; Squire SB; Beyers N; Madan J
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1377-1385. PubMed ID: 27725051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving rifampicin-resistant tuberculosis diagnosis using Xpert
    Dunbar R; Naidoo P; Beyers N; Langley I
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):890-898. PubMed ID: 29991398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis.
    Page AL; Ardizzoni E; Lassovsky M; Kirubi B; Bichkova D; Pedrotta A; Lastrucci C; de la Tour R; Bonnet M; Varaine F
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1078-83, i-iii. PubMed ID: 26260829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries.
    Ardizzoni E; Fajardo E; Saranchuk P; Casenghi M; Page AL; Varaine F; Kosack CS; Hepple P
    PLoS One; 2015; 10(12):e0144656. PubMed ID: 26670929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.
    Thompson RR; Nalugwa T; Oyuku D; Tucker A; Nantale M; Nakaweesa A; Musinguzi J; Reza TF; Zimmer AJ; Ferguson O; Turyahabwe S; Joloba M; Cattamanchi A; Katamba A; Dowdy DW; Sohn H
    Lancet Glob Health; 2023 Feb; 11(2):e278-e286. PubMed ID: 36669808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil.
    Pinto M; Steffen RE; Cobelens F; van den Hof S; Entringer A; Trajman A
    Int J Tuberc Lung Dis; 2016 May; 20(5):611-8. PubMed ID: 27084814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Xpert MTB/RIF assay for diagnosis of tuberculosis and rifampin resistance in county-level laboratories in Hunan province, China.
    Hu P; Bai L; Liu F; Ou X; Zhang Z; Yi S; Chen Z; Gong D; Liu B; Guo J; Tan Y
    Chin Med J (Engl); 2014; 127(21):3744-50. PubMed ID: 25382330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.
    Shah M; Dowdy D; Joloba M; Ssengooba W; Manabe YC; Ellner J; Dorman SE
    AIDS; 2013 Nov; 27(18):2883-92. PubMed ID: 25119690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.
    Mavenyengwa RT; Shaduka E; Maposa I
    Infect Dis Poverty; 2017 Jan; 6(1):13. PubMed ID: 28086955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1115-24, i-xv. PubMed ID: 26260835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.
    Durovni B; Saraceni V; van den Hof S; Trajman A; Cordeiro-Santos M; Cavalcante S; Menezes A; Cobelens F
    PLoS Med; 2014 Dec; 11(12):e1001766. PubMed ID: 25490549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling.
    Ejalu DL; Irioko A; Kirabo R; Mukose AD; Ekirapa E; Kagaayi J; Namutundu J
    BMJ Open; 2022 Aug; 12(8):e059823. PubMed ID: 35998960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Xpert(®) MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosis.
    Kim YW; Seong MW; Kim TS; Yoo CG; Kim YW; Han SK; Yim JJ
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1216-21. PubMed ID: 26459536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia.
    Biadglegne F; Mulu A; Rodloff AC; Sack U
    Tuberculosis (Edinb); 2014 Sep; 94(5):502-5. PubMed ID: 24931451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.